The intersection of artificial intelligence and biotechnology just saw a major capital infusion, as San Francisco Bay Area-based Xaira Therapeutics announced it has raised $550.0M in a Series B funding round. The integrated company is building an ambitious platform to learn the "language of life," aiming to transform how diseases are treated by rethinking the entire drug discovery and development process.
Xaira brings together leading talent across machine learning research, expansive data generation, and robust therapeutic product development to achieve its goals.















